Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese
Status:
Not yet recruiting
Trial end date:
2023-07-10
Target enrollment:
Participant gender:
Summary
This is a phase I clinical bridging trial, randomized，double-blind，placebo-controlled，single
ascending does/ mulelple ascending does study of CS0159 to evaluate the
safety,tolerability,pharmacokynetics,pharmacodynamices, and food effect in healthy subjects。